Officials at biotechnology firm Genzyme are debating financing a clinical trial for another adaptation of a medicinal gadget called Synvisc. The trial is lavish and the chances of achievement are not high, but rather the upside is significant. The case introduces a typical business inquiry: contribute or not? The case powers students to grapple with various complex issues and dissect the financials of their choices.
1. Executive Summary
2. Analysis of the current situation
3. Key Issues
5. Marketing Strategies
6. Action Plan
7. Expected Results
8. Control Mechanisms and Outlook